Heart Test Net Income Over Time
| HSCS Stock | USD 2.99 0.17 6.03% |
With this module, investors can use any or all of fundamental ratio historical patterns as a complementary method for asset selection as well as a tool for deciding entry and exit points. Many technical investors use fundamentals to limit their universe of possible portfolio assets.
Check out Heart Test Performance and Heart Test Correlation. Is there potential for Health Care Equipment & Supplies market expansion? Will Heart introduce new products? Factors like these will boost the valuation of Heart Test. Market participants price Heart higher when confident in its future expansion prospects. Understanding fair value requires weighing current performance against future potential. All the valuation information about Heart Test listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (6.56) | Revenue Per Share | Quarterly Revenue Growth 6.538 | Return On Assets | Return On Equity |
Understanding Heart Test Laboratories requires distinguishing between market price and book value, where the latter reflects Heart's accounting equity. The concept of intrinsic value - what Heart Test's is actually worth based on fundamentals - guides informed investors toward better entry and exit points. Analysts utilize numerous techniques to assess fundamental value, seeking to purchase shares when trading prices fall beneath estimated intrinsic worth. Market sentiment, economic cycles, and investor behavior can push Heart Test's price substantially above or below its fundamental value.
Please note, there is a significant difference between Heart Test's value and its price as these two are different measures arrived at by different means. Investors typically determine if Heart Test is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. In contrast, Heart Test's trading price reflects the actual exchange value where willing buyers and sellers reach mutual agreement.
Cross Equities Net Income Analysis
Compare Heart Test Laboratories and related stocks such as PAVmed Inc, STRATA Skin Sciences, and Matinas BioPharma Net Income Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| PAVM | (548.8 K) | (548.8 K) | (548.8 K) | (548.8 K) | (548.8 K) | (1.8 M) | (5.7 M) | (9.5 M) | (18 M) | (15.9 M) | (34.3 M) | (50.3 M) | (89 M) | (64.2 M) | 39.8 M | 35.8 M | 37.6 M |
| SSKN | (2.3 M) | (20.4 M) | (22.7 M) | (25.9 M) | (16 M) | (27.9 M) | (3.3 M) | (21.5 M) | (4 M) | (3.8 M) | (4.4 M) | (2.7 M) | (5.5 M) | (10.8 M) | (10.1 M) | (9.1 M) | (9.5 M) |
| MTNB | (116.1 K) | (116.1 K) | (116.1 K) | (3.7 M) | (10.2 M) | (9.1 M) | (7.6 M) | (15.5 M) | (14.1 M) | (17.4 M) | (22.4 M) | (23.3 M) | (21 M) | (22.9 M) | (24.3 M) | (21.8 M) | (22.9 M) |
| BCLI | (25.6 K) | (3.9 M) | (3.4 M) | (4.9 M) | (9.2 M) | (8.5 M) | (5 M) | (5 M) | (13.9 M) | (23.3 M) | (31.8 M) | (24.5 M) | (23.7 M) | (17.2 M) | 11.6 M | 10.5 M | 11 M |
| AMIX | (13.3 M) | (13.3 M) | (13.3 M) | (13.3 M) | (13.3 M) | (13.3 M) | (13.3 M) | (13.3 M) | (13.3 M) | (13.3 M) | (13.3 M) | (13.3 M) | (2 M) | (15.4 M) | (11.4 M) | (10.3 M) | (10.8 M) |
| IBO | (408.3 K) | (408.3 K) | (408.3 K) | (408.3 K) | (408.3 K) | (408.3 K) | (408.3 K) | (408.3 K) | (98.1 K) | (590.1 K) | (760.1 K) | (3.9 M) | (7.1 M) | (4.3 M) | (2.1 M) | (1.8 M) | (1.9 M) |
| MYNZ | (957.1 K) | (957.1 K) | (957.1 K) | (957.1 K) | (957.1 K) | (957.1 K) | (957.1 K) | (957.1 K) | (957.1 K) | (957.1 K) | (586.9 K) | (11.7 M) | (26.5 M) | (26.3 M) | (21.7 M) | (19.5 M) | (20.5 M) |
| BMRA | (1.9 M) | 548.4 K | 537 K | (215.7 K) | (331.4 K) | (1.5 M) | (908.6 K) | (1.5 M) | (2.4 M) | (2.3 M) | (7.4 M) | (4.5 M) | (7.1 M) | (6 M) | (5 M) | (4.5 M) | (4.3 M) |
| NRSN | (1.2 M) | (1.2 M) | (1.2 M) | (1.2 M) | (1.2 M) | (1.2 M) | (1.2 M) | (1.2 M) | (1.2 M) | (1.2 M) | (2.8 M) | (4 M) | (12.3 M) | (10.1 M) | (10.2 M) | (9.2 M) | (9.6 M) |
Heart Test Laboratories and related stocks such as PAVmed Inc, STRATA Skin Sciences, and Matinas BioPharma Net Income description
Net income is one of the most important fundamental items in finance. It plays a large role in Heart Test Laboratories financial statement analysis. It represents the amount of money remaining after all of Heart Test Laboratories operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue.My Equities
My Current Equities and Potential Positions
| Heart Test Laboratories | HSCS |
Specialization | Health Care, Health Care Equipment & Services |
| Business Address | 550 Reserve Street, |
| Exchange | NASDAQ Exchange |
USD 2.99
Additional Tools for Heart Stock Analysis
When running Heart Test's price analysis, check to measure Heart Test's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Heart Test is operating at the current time. Most of Heart Test's value examination focuses on studying past and present price action to predict the probability of Heart Test's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Heart Test's price. Additionally, you may evaluate how the addition of Heart Test to your portfolios can decrease your overall portfolio volatility.